THORNTON & ROSS LTD ACQUIRES "FLEXITOL" BRAND FROM LACORIUM HEALTH

  • 23/06/2014
  • Press Release

Huddersfield based Thornton & Ross Ltd. is pleased to announce that it has completed the purchase of the Flexitol brand in the UK & Eire from LaCorium Health. Flexitol is a well established and successful range of dry skin treatments, which is best known for its footcare products. The acquisition is effective from the 16th June 2014.

The purchase includes all intellectual property, trade marks, and stocks relating to the brand in the UK and Eire. Thornton & Ross will take over the marketing of the brand with immediate effect.

Commenting on the purchase, Dieno George the Chief Executive of Thornton & Ross, said that Flexitol would add to the company's growing range of well-known UK brands. Mr George added that Flexitol would also benefit from Thornton & Ross' considerable strength and experience in manufacturing pharmaceutical quality cream products and medical devices.

Thornton & Ross Ltd. produces a number of medicinal and household products, including Covonia cough medicines, Hedrin head lice treatment, the Care range of medicines and the Cetraben and Zero dermatological brands, as well as Zoflora a fragranced disinfectant product. The business is part of STADA Arzneimittel AG which is based in Bad Vilbel, Frankfurt, Germany.

Luc Slegers, the STADA Regional Director for Europe commented that the acquisition is part of the STADA Group’s development of a strong branded portfolio, and would build upon the Centre of Excellence for OTC and prescription dermatology, which the company has established at Thornton & Ross as part of the STADA Group.

LaCorium is based in Australia and will retain the rights to Flexitol in all territories outside the UK and Eire.